PI3K/AKT/ERK/CREB activator 1

Cat. No.: HY-181672: Ficha de datos Instrucciones de manejo
FAQs
Technical Support

PI3K/AKT/ERK/CREB activator 1 is an orally active PI3K/AKT/ERK/CREB pathway activator. PI3K/AKT/ERK/CREB activator 1 maintains neuronal survival and function, promotes neuronal proliferation, restores the viability of damaged neurons, and facilitates synapse formation. PI3K/AKT/ERK/CREB activator 1 alleviates neuroinflammation by reducing the levels of pro-inflammatory cytokines, preserves synaptic ultrastructure and restores spatial memory in Alzheimer's disease models. PI3K/AKT/ERK/CREB activator 1 can be used in research related to Alzheimer's disease.

Para uso exclusivo en investigación. No vendemos a pacientes.

PI3K/AKT/ERK/CREB activator 1 Estructura química

No. CAS : 3107309-22-5

Tamaño		Stock
MOQ		Minimum order quantity
50 mg		Obtener un presupuesto
100 mg		Obtener un presupuesto
250 mg		Obtener un presupuesto
Other size		Obtener un presupuesto

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Recomendaciones destacadas

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas PI3K:

Ver todas las isoformas

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

Ver todos los productos específicos de isoformas Akt:

Ver todas las isoformas

Akt Akt1 Akt2 Akt3

Ver todos los productos específicos de isoformas ERK:

Ver todas las isoformas

ERK ERK1 ERK2 ERK5 ERK8

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

In Vitro

PI3K/AKT/ERK/CREB activator 1 (Compound A18) (60 μM; 48 h) potently promotes the proliferation of SH-SY5Y cells, and increases cell viability by 29.4% after treatment at 60 μM for 48 h^[1].
PI3K/AKT/ERK/CREB activator 1 (60 μM; 48 h) significantly rescues SH-SY5Y cells damaged by Rotenone (HY-B1756), and increases cell viability by 42.5% at 60 μM for 48 h^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	SH-SY5Y
Concentration:	60 μM
Incubation Time:	48 h
Result:	Enhanced SH-SY5Y cell viability by 29.4% compared to the control group, with a statistically significant effect.

Cell Viability Assay^[1]

Cell Line:	SH-SY5Y (Rotenone-injured)
Concentration:	60 μM
Incubation Time:	48 h (added 4 h after 5 μM Rotenone exposure)
Result:	Increased the viability of rotenone-injured SH-SY5Y cells by 42.5% compared to the rotenone-only control group, with a highly statistically significant effect.

Parmacokinetics

Species	Dose	Route	T_1/2	V_d/F	CL/F
Mice^[1]	25 mg/kg	p.o.	14.40 h	0.00307 mg/L	15.69 L/h/kg

In Vivo

PI3K/AKT/ERK/CREB activator 1 (Compound A18) (25-100 mg/kg; p.o.; once daily for 23 consecutive days) exhibits potent multimodal therapeutic effects in the Aβ_1-42-induced Alzheimer's disease mouse model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 (male, 3-month-old, 28-32 g, SPF, wild-type, Alzheimer's disease model via unilateral intracerebroventricular injection of aggregated Aβ_1-42 peptide)^[1]
Dosage:	25 mg/kg/day; 50 mg/kg/day; 100 mg/kg/day
Administration:	oral gavage; daily; 23 consecutive days
Result:	Significantly increased platform crossings and target quadrant occupancy at 25 mg/kg/day, with platform crossing frequency following a dose-dependent trend: 25 mg/kg > 50 mg/kg > 100 mg/kg. Reduced escape latency and enhanced spatial orientation compared to the Aβ-only group across all treated groups. Reversed Aβ_1-42-induced neurodegeneration, with higher neuronal density in the hippocampal CA1 region compared to the Aβ-only group , and preserved intact synaptic ultrastructure with defined presynaptic membranes and ordered vesicles. Suppressed Aβ-induced glial activation, reducing Iba-1⁺ microglial density and GFAP immunofluorescence intensity, and downregulated hippocampal TNF-α and IL-6 mRNA levels by 40-60%. Increased hippocampal protein levels: CHRM5, phosphorylated PI3K, AKT, ERK, phosphorylated CREB, and synaptophysin. Facilitated weight recovery in Aβ-injected mice, with the 25 mg/kg group showing the most rapid recovery to levels comparable to the blank control by day 21.

Peso molecular

905.06

Fòrmula

C₄₇H₇₃N₂O₁₃P

No. CAS

3107309-22-5

SMILES

CCCCCCCCCCCCCCOC1=CC=C(C(OC[C@@H](OC(CCC/C=C/C/C=C/C/C=C/C/C=C/C/C=C/CC)=O)COP(OC[C@@H](N)C(O)=O)(O)=O)=O)C=C1[N+]([O-])=O

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureza y Documentación

Instrucciones de manejo (2659 KB)

Referencias

[1]. Lin Y, et al. Design, synthesis, and investigation of anti-Alzheimer's activity and molecular mechanisms of phosphatidylserine derivatives. Eur J Med Chem. 2026;307:118676. [Content Brief]